Among the seven most frequently amplified HMTs, the frequencies of NSD1 and PRDM6 of high-level amplification were markedly higher in 528 ccRCC with more than 13.45% of tumor samples exhibiting amplificated when compared with that of 288 pRCC and 66 chRCC subtypes, which was less than 1.04% of tumor samples (Fig. 1A). This evidence concerns the gene PRDM6 and chromophobe renal cell carcinoma.